Ian Campbell

University of Melbourne

Papers

1

Total Citations

13

H-Index

1

About

Dr. Ian Campbell is a leading translational researcher in gynecologic oncology, with a focused expertise in the molecular characterization and therapeutic targeting of rare ovarian cancers. His major contributions center on low-grade serous ovarian carcinoma (LGSOC), a disease distinct from the more common high-grade serous carcinoma. Dr. Campbell’s landmark 2024 study, “High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma,” has already garnered 13 citations, demonstrating its immediate impact. This work addressed a critical gap: pivotal clinical trials for epithelial ovarian cancer have historically excluded sufficient LGSOC cases, leaving patients with limited, evidence-based options. By employing high-throughput screening, Dr. Campbell identified promising new drug candidates tailored to LGSOC’s unique molecular profile, offering a path toward more effective, personalized therapies. His research not only advances the understanding of this understudied malignancy but also provides a practical framework for drug repurposing and discovery. For students and researchers, Dr. Campbell’s work exemplifies how targeted, disease-specific approaches can transform outcomes in rare cancers, bridging the gap between molecular biology and clinical application.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma
13 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: University of Melbourne

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago